Sandoz Picks Up Pfizer's Infliximab Biosimilar
This article was originally published in Scrip
Executive Summary
Novartis AG's generics business Sandoz is bulking up its budding biosimilars portfolio by acquiring the rights to Pfizer Inc.'s PF-06438179, a biosimilar version of infliximab (Johnson and Johnson's Remicade), in Europe.